Suppr超能文献

在择期神经外科手术中常规凝血酶原时间筛查的价值。

On the value of routine prothrombin time screening in elective neurosurgical procedures.

机构信息

Department of Neurosurgery, Johann Wolfgang Goethe University, Frankfurt/Main, Germany.

出版信息

Neurosurg Focus. 2012 Nov;33(5):E9. doi: 10.3171/2012.7.FOCUS12219.

Abstract

OBJECT

The authors performed a study to evaluate whether preoperative assessment of prothrombin time (PT) is mandatory in patients undergoing routinely planned neurosurgical procedures.

METHODS

The charts of all patients admitted to general wards of the authors' department for routinely planned surgery (excluding trauma and ICU patients) between 2006 and 2010 were retrospectively reviewed. The authors assessed preoperative PT and the clinical courses of all patients, with special consideration for patients receiving coagulation factor substitution. All cases involving hemorrhagic complications were analyzed in detail with regard to pre- and postoperative PT abnormalities. Prothrombin time was expressed as the international normalized ratio, and values greater than 1.28 were regarded as elevated.

RESULTS

Clinical courses and PT values of 4310 patients were reviewed. Of these, 33 patients (0.7%) suffered hemorrhagic complications requiring repeat surgery. Thirty-one patients (94%) had a normal PT before the initial operation, while 2 patients had slightly elevated PT values of 1.33 and 1.65, which were anticipated based on the patient's history. In the latter 2 cases, surgery was performed without prior correction of PT. Preoperatively, PT was elevated in 78 patients (1.8%). In 73 (93.6%) of the 78 patients, the PT elevation was expected and explained by each patient's medical history. In only 5 (0.1%) of 4310 patients did we find an unexpected PT elevation (mean 1.53, range 1.37-1.74). All 5 patients underwent surgery without complications, while 2 had received coagulation factor substitution preoperatively, as requested by the surgeon, because of an estimated risk of bleeding complications. None of the 5 patients received coagulation factor substitution postoperatively, and later detailed laboratory studies ruled out single coagulation factor deficiencies. There was no statistically significant association between preoperatively elevated PT levels and the occurrence of hemorrhagic complications (p = 0.12). Before the second procedure but not before the initial operation, 4 (12%) of the 33 patients had elevated PT.

CONCLUSIONS

The findings suggest that the value of preoperative PT testing is limited in patients in whom a normal history can be ascertained. Close postoperative PT control is necessary in every neurosurgical patient, and better tests need to be developed to identify patients who are prone to hemorrhagic complications.

摘要

目的

作者进行了一项研究,以评估在接受常规计划神经外科手术的患者中是否需要进行术前凝血酶原时间(PT)评估。

方法

回顾性分析了 2006 年至 2010 年间作者所在科室普通病房接受常规手术(不包括创伤和 ICU 患者)的所有患者的图表。作者评估了所有患者的术前 PT 和临床过程,特别考虑了接受凝血因子替代治疗的患者。详细分析了所有涉及出血并发症的病例,包括术前和术后 PT 异常。凝血酶原时间以国际标准化比值表示,大于 1.28 被认为升高。

结果

回顾了 4310 名患者的临床过程和 PT 值。其中,33 名(0.7%)患者发生需要再次手术的出血性并发症。31 名(94%)患者在初始手术前 PT 正常,而 2 名患者的 PT 值略高,分别为 1.33 和 1.65,这是根据患者的病史预测的。在后 2 例中,手术在没有纠正 PT 的情况下进行。术前,78 名患者(1.8%)的 PT 升高。在 78 名患者中,73 名(93.6%)的 PT 升高是根据每个患者的病史预期的并得到了解释。在 4310 名患者中,只有 5 名(0.1%)患者发现了意外的 PT 升高(平均 1.53,范围 1.37-1.74)。所有 5 名患者均未出现手术并发症,而 2 名患者因预计出血并发症风险较高,术前根据外科医生的要求接受了凝血因子替代治疗。术后 5 名患者均未接受凝血因子替代治疗,随后详细的实验室研究排除了单一凝血因子缺乏症。术前 PT 升高与出血性并发症的发生无统计学显著相关性(p=0.12)。在第二次手术前(而非初次手术前),33 名患者中有 4 名(12%)PT 升高。

结论

研究结果表明,在能够确定正常病史的患者中,术前 PT 检测的价值有限。每个神经外科患者都需要密切的术后 PT 控制,需要开发更好的测试来识别易发生出血性并发症的患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验